Last month we were diligently completing the primary screening phase of our NPC campaign: 50,000 compounds across 3 models in 6 months.
Our NPC worm screen is nearing the home stretch. pic.twitter.com/eBOTpUq1N9
— Perlara (@PerlaraPBC) May 1, 2015
Team Worm incubates another batch of 384-well plates, including technical replicates. Validation of “pre-hits” underway in parallel.
— Perlara (@PerlaraPBC) May 2, 2015
If it’s Friday at 5:30pm, chances are we’re at PLab Happy Hour at the Dogpatch Saloon. A round of PLab’s unofficial official drink (The Whiskey Snap) are even better when we’re toasting an interesting (and reproducible!) result.
— Kiran Singh (@Snarik) May 6, 2015
An impromptu evening at the ballpark. Weekday night company culture at its best!
A validated hit from our NPC worm screen: (L to R) neg control, replicate 1, replicate 2. Adults blue, larvae yellow. pic.twitter.com/cO4U1XVJxq
— Perlara (@PerlaraPBC) May 12, 2015
Pre-hits graduate to bona fide hits.
Excited to announce that @materechm will be PLab's summer intern starting later this month! She'll be working on yeast ALS models and more.
— Perlara (@PerlaraPBC) May 14, 2015
Maria Teresa Chavez is working on computational projects and on ALS yeast model pilot screens. She’ll be updating the world about her research progress on her blog and on Twitter.
Team Fly developed a more sensitive pupal survival secondary assay to confirm that pre-hits are real hits.
Final worm and fly sorts! Finishing up the primary screens 🙂 @PerlsteinLab pic.twitter.com/FDQuuFFDYz
— Nina DiPrimio (@NinaDiPrimio) May 20, 2015
The BioSorter was pushed to the max to get this last batch of primary screening plates processed.
— Tara Mandalaywala (@tmandalaywala) May 21, 2015
Ethan spoke to the postdocs at NYU about PLab and played the “Gene’s Eye View” rap video by Baba Brinkman as inspiration.
Raising awareness for NGLY1 in NYC pic.twitter.com/mDpjwFgLao
— Ethan Perlstein (@eperlste) May 22, 2015
Patient advocacy selfie.
The cost of orphan drugs per patient per year (biologics + small molecules) between 1983 and 2014: pic.twitter.com/8tM1c8JYg5
— Perlara (@PerlaraPBC) May 27, 2015
Kiran assembled a dataset of orphan drugs approved for a monogenic disease, e.g., Kalydeco. Here’s one of the first plots he generated. Check out our blog stream for the first two installments.